Associations Between Clinical Outcomes and a Recently Proposed Adult Congenital Heart Disease Anatomic and Physiological Classification System

Cara L. Lachtrupp, MD; Anne Marie Valente, MD; Michelle Gurvitz, MD; Michael J. Landzberg, MD; Sarah B. Brainard, BA; Fred M. Wu, MD; Dorothy D. Pearson, PA-C; Keith Taillie, PA-C; Alexander R. Opotowsky, MD, MMSc

BACKGROUND: American Heart Association and American College of Cardiology consensus guidelines introduce an adult congenital heart disease anatomic and physiological (AP) classification system. We assessed the association between AP classification and clinical outcomes.

METHODS AND RESULTS: Data were collected for 1000 outpatients with ACHD prospectively enrolled between 2012 and 2019. AP classification was assigned based on consensus definitions. Primary outcomes were (1) all-cause mortality and (2) a composite of all-cause mortality or nonelective cardiovascular hospitalization. Cox regression models were developed for AP classification, each component variable, and additional clinical models. Discrimination was assessed using the Harrell C statistic. Over a median follow-up of 2.5 years (1.4–3.9 years), the composite outcome occurred in 185 participants, including 49 deaths. Moderately or severely complex anatomic class (class II/III) and severe physiological stage (stage D) had increased risk of the composite outcome (AP class IId and IIId hazard ratio, 4.46 and 3.73, respectively, versus IIC). AP classification discriminated moderately between patients who did and did not suffer the composite outcome (C statistic, 0.69 [95% CI, 0.67–0.71]), similar to New York Heart Association functional class and NT-proBNP (N-terminal pro-B-type natriuretic peptide); it was more strongly associated with mortality (C statistic, 0.81 [95% CI, 0.78–0.84]), as were NT-proBNP and functional class. A model with AP class and NT-proBNP provided the strongest discrimination for the composite outcome (C statistic, 0.73 [95% CI, 0.71–0.75]) and mortality (C statistic, 0.85 [95% CI, 0.82–0.88]).

CONCLUSIONS: The addition of physiological stage modestly improves the discriminative ability of a purely anatomic classification, but simpler approaches offer equivalent prognostic information. The AP system may be improved by addition of key variables, such as circulating biomarkers, and by avoiding categorization of continuous variables.

Key Words: adult congenital heart disease ■ classification ■ cohort study ■ congenital heart disease ■ guidelines ■ mortality ■ outcomes

Patients with adult congenital heart disease (ACHD) are a growing population with high healthcare resource use. ACHD describes a broad spectrum of diagnoses associated with distinct clinical courses and many potential complications. Consequently, it has been challenging to identify a broadly applicable classification schema for clinical management and risk stratification. The most commonly used ACHD classification system, initially proposed at the 32nd Bethesda
Lachtrupp et al  ACHD Anatomic Physiological Class and Prognosis

Conference, are based mainly on congenital heart disease (CHD) anatomy.6 There is little consideration of other variables with implications for management and prognosis, including prior interventions, complications, comorbidities, and current functional status.6,7

The anatomic and physiological (AP) classification system, introduced in the 2018 American Heart Association/American College of Cardiology ACHD guidelines, attempts to address the shortcomings of the anatomic classification. The AP system includes 2 components: anatomic class (AnatC) and physiological stage (PhyS). AnatC is largely anatomic classification similar to the 32nd Bethesda Conference scheme. Conversely, PhyS reflects a distinct dimension of the status of patient with ACHD, combining aspects of physiology, complications, and functional status.6,8

Patients are assigned an AnatC of I to III and a PhyS of A to D; therefore, patients fall into one of 12 possible categories (IA–IID).8

To assign PhyS for a given patient, a clinician considers a broad array of variables.8 This dimension and some of its component variables, such as New York Heart Association functional class (NYHA FC), would be expected to be associated with clinical outcomes, including early postoperative and longterm mortality.9,10 However, it is not yet clear how well the AP system compares with other approaches, particularly in terms of outpatient follow-up. A recent study from our group highlighted obstacles to implementing PhyS in practice, including ambiguities in definitions resulting in interobserver variability.11

The present study of an outpatient ACHD referral cohort has 4 aims: (1) to assess the distribution of the AP system classifications and component variables; (2) to assess the ability of the AP system, especially PhyS, to predict outcomes important to the care of patients with ACHD; (3) to compare the AP system to other prognostic models and variables currently used in clinical practice; and (4) to identify areas of potential improvement for future iterations of the AP system.

METHODS

Data Disclosure Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Description of the Cohort

Patients enrolled in the BACH (Boston ACHD Biobank) were included in the current study. The BACH is a prospective cohort study that enrolled outpatients ≥18 years old with congenital heart disease at Boston Children’s or Brigham and Women’s Hospitals between March 2012 and January 2019. We obtained written informed consent from each participant or their legally authorized representative. Details of the design and methodology of this cohort study have been published.12 Additional data were collected to assign AP classification by chart review accurately. This study was approved by Boston Children’s Hospital’s Institutional Review Board with a formal reliance agreement between the Partners HealthCare/Brigham and Women’s Hospital and Boston Children’s Hospital institutional review boards.

Data Collection and AP Assignment

Baseline data, including CHD diagnosis, clinical characteristics, and clinically indicated testing were collected from the electronic health record at the time of enrollment and reflect the index visit.12 Information about any

CLINICAL PERSPECTIVE

What Is New?

• In 2018, American Heart Association and American College of Cardiology guidelines proposed an anatomic and physiological adult congenital heart disease classification, integrating traditional concepts of anatomic complexity with markers of pathophysiological severity.
• The current analysis of 1000 adults with congenital heart disease reports that physiological stage does add discriminative power to anatomic classification alone.
• However, the anatomic and physiological classification did not outperform simpler approaches to predicting outcome, such as measurement of circulating natriuretic peptides.

What Are the Clinical Implications?

• The proposed American Heart Association and American College of Cardiology adult congenital heart disease anatomic and physiological classification scheme provides a conceptual framework for personalizing adult congenital heart disease care, but further tuning and validation is required before large-scale clinical implementation.

Nonstandard Abbreviations and Acronyms

| Abbreviation | Definition |
|--------------|------------|
| ACHD         | adult congenital heart disease |
| AnatC        | anatomic class |
| AP           | anatomic and physiological |
| NYHA FC      | New York Heart Association functional class |
| PhyS         | physiological stage |

CLINICAL PERSPECTIVE

What Is New?

• In 2018, American Heart Association and American College of Cardiology guidelines proposed an anatomic and physiological adult congenital heart disease classification, integrating traditional concepts of anatomic complexity with markers of pathophysiological severity.
• The current analysis of 1000 adults with congenital heart disease reports that physiological stage does add discriminative power to anatomic classification alone.
• However, the anatomic and physiological classification did not outperform simpler approaches to predicting outcome, such as measurement of circulating natriuretic peptides.

What Are the Clinical Implications?

• The proposed American Heart Association and American College of Cardiology adult congenital heart disease anatomic and physiological classification scheme provides a conceptual framework for personalizing adult congenital heart disease care, but further tuning and validation is required before large-scale clinical implementation.

Nonstandard Abbreviations and Acronyms

| Abbreviation | Definition |
|--------------|------------|
| ACHD         | adult congenital heart disease |
| AnatC        | anatomic class |
| AP           | anatomic and physiological |
| NYHA FC      | New York Heart Association functional class |
| PhyS         | physiological stage |
outcomes, interventions, and hospitalizations that are reported to the patient’s BACH physician is collected at regular intervals for each patient. For this study, we collected additional information about diagnostic tests, anatomy, and physiologic data as needed to assign AnatC and PhyS. When not explicitly described in the guideline document, AP category definitions were developed based on existing literature and expert opinion (Tables S1 and S2). These were discussed by an expert panel (M.G., M.J.L., A.R.O., and A.M.V.) and approved by consensus. Each patient was assigned an AP category according to the most severe clinical features at the time of their index visit. These classifications were not changed for follow-up analysis.

Outcomes of Interest
The primary outcomes of interest were: (1) all-cause mortality and (2) a composite outcome of all-cause mortality or nonselective cardiovascular hospitalization. We defined nonselective cardiovascular hospitalization as overnight hospital admission for heart failure, arrhythmia, thromboembolism, bleeding event, or any other complications related to their CHD (eg, endocarditis). This end point was satisfied at the first hospitalization or death. Secondary outcomes, assessed separately, included: (1) new or worsening heart failure, defined as requiring hospitalization or an increase/initiation of diuretic therapy; (2) arrhythmia event resulting in hospitalization; pacemaker or defibrillator placement; electrical cardioversion; or initiation/change of antiarrhythmic medications; (3) thromboembolic event requiring hospitalization or new therapy; (4) bleeding event resulting in hospitalization or therapy/intervention; and (5) cardiac catheter-based or surgical intervention.

Statistical Analysis
Variables were compared across AnatC and PhyS. Continuous variables are presented as mean (standard deviation) for normally distributed variables and as median (25th, 75th percentile) for nonnormally distributed variables and analyzed using Welch’s ANOVA. Categorical variables are presented as number (percentage) and compared between categories using the Fisher exact test.

We modeled the relationship between AP class and each primary and secondary outcome using Cox proportional hazards methods and calculated Harrell C statistic to assess the discriminative power of the AP model and each other model (listed below). AP classification was assessed as an unordered variable. Complete case analysis was used for Cox regression. Additionally, receiver operating characteristic curves were plotted, with an event defined as sustaining the outcome of interest within 1 year of follow-up; these analyses included only participants who had at least 1 year of event-free survival or had sustained the event of interest within 1 year. In addition to AP classification, other models assessed include AnatC alone, PhyS alone, Bethesda classification, NT-proBNP (N-terminal pro-B-type natriuretic peptide), and NYHA FC. We also assessed the predictive value of PhyS component variables, including maximal aortic diameter, exercise limitation (percent predicted, Wasserman equations), and resting arterial oxygen saturation. Cardiopulmonary exercise testing data were available for only 68.3% of patients from the 5 years before enrollment, so cardiopulmonary exercise testing variables were not included in the analysis. NT-proBNP was measured as part of a separate research study in 2018; patients enrolled after 2018 did not have NT-proBNP measured. For the subset of participants without data on NT-proBNP (17.2%), we used multiple imputation by chained equations (n=20 imputations, Table S3) to impute log2 NT-proBNP. Analyses used R, version 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria).

RESULTS
Description of the Cohort
There were 1153 patients enrolled and had sufficient data to assign AP classification. One hundred fifty-three patients were excluded from analysis because of incomplete follow-up data. Of the 1000 subjects analyzed, the median age at enrollment was 35.25 years (25th, 75th percentiles: 27.2, 47.9 years); 48.5% were women. The most common CHD diagnoses were left-sided outflow tract lesions (n=212, 21.2%), tetralogy of Fallot (n=176, 17.6%), and single ventricle heart disease with Fontan physiology (n=133, 13.3%). Many patients, 52.3%, were classified as moderate complexity (AnatC II), and only 95 (9.5%) as simple (AnatC=I). Most patients, 57.4%, were classified as PhyS C, whereas only 5.7% were PhyS A.

More complex AnatC tended to be associated with more severe PhyS, though exceptions were common (eg, 48.4% of AnatC I patients were PhyS C or D) (Table 1). Although there was no apparent relationship between AnatC and NYHA FC, worse PhyS was strongly associated with higher NYHA FC (Table 2). PhyS was also associated with various complications and comorbidities such as heart failure, pulmonary hypertension, type 2 diabetes, liver cirrhosis, and chronic kidney disease. Worse PhyS was also associated with higher NT-proBNP (Table 2).

Comparison of AnatC and Bethesda classifications revealed 64 patients with isolated bicuspid aortic valve who were classified as simple CHD per Bethesda and moderate CHD per the AP classification, and 6 patients...
|                | I                | II               | III              | P value | Missing (%) |
|----------------|------------------|------------------|------------------|---------|-------------|
| No.            | 95               | 523              | 382              |         |             |
| Age, y         | 37.9 [29.0, 54.2]| 38.4 [29.0, 51.7]| 31.5 [24.8, 40.4]| <0.001  | 0.0         |
| Sex, % women   | 55 (57.9)        | 258 (49.3)       | 172 (45.0)       | 0.069   | 0.0         |
| Race (%)       |                  |                  |                  | 0.560   | 2.0         |
| Non-White*     | 6 (6.5)          | 25 (4.9)         | 24 (6.3)         |         |             |
| Unknown        | 8 (8.7)          | 54 (10.6)        | 49 (12.9)        |         |             |
| White          | 78 (84.8)        | 430 (84.5)       | 306 (80.7)       |         |             |
| BMI, kg/m²     | 26.6 [23.5, 29.1]| 26.9 [23.3, 31.1]| 24.8 [22.3, 28.6]| <0.001  | 0.8         |
| Systolic blood pressure, mm Hg | 121.0 [112.0, 130.0] | 122.0 [112.0, 130.0] | 118.0 [109.0, 125.0] | <0.001  | 0.5         |
| Diastolic blood pressure, mm Hg | 69.0 [61.5, 77.5] | 69.0 [61.0, 75.8] | 67.0 [59.0, 73.0] | <0.001  | 0.5         |
| NYHA FC (%)    |                  |                  |                  | 0.290   | 0.0         |
| I              | 73 (76.8)        | 410 (78.4)       | 276 (72.3)       |         |             |
| II             | 19 (20.0)        | 96 (18.4)        | 93 (24.3)        |         |             |
| III/IV         | 3 (3.2)          | 17 (3.3)         | 13 (3.4)         |         |             |
| CHD diagnosis (%) |              |                  |                  | <0.001  | 0.0         |
| Tetralogy of Fallot | 0 (0.0) | 136 (26.0) | 40 (10.5) |         |             |
| Left-sided valve/outflow tract disease (excluding coarctation) | 0 (0.0) | 117 (22.4) | 6 (1.6) |         |             |
| Fontan         | 0 (0.0)          | 0 (0.0)          | 133 (34.8)       |         |             |
| Atrial septal defect | 27 (28.4) | 59 (11.3) | 0 (0.0) |         |             |
| Coarctation    | 0 (0.0)          | 89 (17.0)        | 0 (0.0)          |         |             |
| Atrial switch for TGA | 0 (0.0) | 0 (0.0) | 57 (14.9) |         |             |
| Ventricular septal defect | 33 (34.7) | 11 (2.1) | 0 (0.0) |         |             |
| DORV           | 0 (0.0)          | 0 (0.0)          | 42 (11.0)        |         |             |
| Valvar pulmonary stenosis | 16 (16.8) | 12 (2.3) | 0 (0.0) |         |             |
| Arterial switch for TGA | 0 (0.0) | 0 (0.0) | 30 (7.9) |         |             |
| Ebstein anomaly | 0 (0.0) | 27 (5.2) | 0 (0.0) |         |             |
| Physiologically corrected TGA | 0 (0.0) | 0 (0.0) | 26 (6.8) |         |             |
| Atrioventricular septal defect | 0 (0.0) | 23 (4.4) | 0 (0.0) |         |             |
| Pulmonary atresia with intact ventricular septum | 0 (0.0) | 0 (0.0) | 17 (4.5) |         |             |
| Eisenmenger physiology | 8 (8.4) | 1 (0.2) | 2 (0.5) |         |             |
| Complex cyanotic, eg, unrepaired double-inlet ventricle | 0 (0.0) | 0 (0.0) | 8 (2.1) |         |             |
| Rastelli procedure for TGA | 0 (0.0) | 0 (0.0) | 9 (2.4) |         |             |
| Other          | 11 (11.6)        | 48 (9.2)         | 12 (3.1)         |         |             |
| Physiological stage (%) |                  |                  |                  | <0.001  | 0.0         |
| A              | 17 (17.9)        | 26 (5.0)         | 14 (3.7)         |         |             |
| B              | 32 (33.7)        | 135 (25.8)       | 66 (17.3)        |         |             |
| C              | 31 (32.6)        | 309 (59.1)       | 234 (61.3)       |         |             |
| D              | 15 (15.8)        | 53 (10.1)        | 68 (17.8)        |         |             |
| Genetic syndrome (%) | 10 (10.5) | 37 (7.1) | 22 (5.8) | 0.254   | 0.0         |
| Heart failure (%) | 0 (0.0) | 19 (3.6) | 21 (5.5) | 0.041   | 0.0         |
| CAD (%)        | 0 (0.0)          | 7 (1.3)          | 0 (0.0)          | 0.040   | 0.0         |

(Continued)
Association With Clinical Outcomes

Over a median follow-up of 2.5 years (25th, 75th percentiles: 1.4–3.9 years), the primary composite outcome of all-cause mortality or nonelective cardiovascular hospitalization occurred in 185 patients, including 49 deaths. Those with and without measurement of NT-proBNP were clinically similar, and the incidence of clinical events per person-year was similar between those who did and did not have NT-proBNP data; however, because of shorter follow-up time for those without NT-proBNP data, a smaller proportion of these participants experienced the primary outcome (Table S4). Kaplan-Meier analysis for the primary composite outcome demonstrated a difference between AnatC III compared to AnatC I and II (Figure 1A); only 8.4% of patients classified as AnatC I suffered an event compared to 26.4% for AnatC III. Similarly, PhyS C and D were both associated with a higher risk for the primary composite outcome compared to PhyS A or B (Figure 1B). The proportion of participants suffering the composite outcome in PhyS A, B, C, and D were 3.5%, 6.9%, 17.9%, and 47.1%, respectively. Of note, there was no statistically significant difference in risk for the primary composite outcome for PhyS A compared with PhyS B ($P=0.41$) (Figure S1).

AnatC in isolation was a poor predictor of adverse outcomes; for the primary composite outcome, the C statistic was 0.57 (95% CI, 0.55–0.59). When comparing C statistic point estimates, AnatC was less strongly associated with this composite outcome than was the original Bethesda classification (C statistic, 0.61 [95% CI, 0.59–0.63]). PhyS was more strongly associated with the composite outcome, with a C statistic of 0.66 (95% CI, 0.64–0.68). The combination of AnatC and PhyS (AP classification) was only modestly better than PhyS alone (C statistic, 0.69 [95% CI, 0.67–0.71]) (Figures 2 and 3A). For all-cause mortality alone, the C statistics for AnatC, PhyS, and AP were 0.62 (95% CI, 0.58–0.66), 0.78 (95% CI, 0.75–0.81), and 0.81 (95% CI, 0.78–0.84), respectively (Figure 3B). Using AP IIC as the reference group (too few patients were classified as IA to serve as a reliable reference), Cox proportional hazards analysis demonstrated a significantly higher hazard for the primary composite outcome for those categorized as IID (hazard ratio [HR], 3.73; 95% CI, 2.25–6.18; $P=0.0001$) and IIID (HR, 4.46; 95% CI: 2.88–6.90; $P<0.0001$) (Table 3). Equivalent analysis with a dependent variable of all-cause mortality or the secondary outcomes followed a similar pattern, with a higher risk for groups IID and IIID for all-cause mortality, heart failure, arrhythmia, thromboembolic event, and bleeding event (Table 3, Table S5).

We then assessed discriminative power of other available predictors for the primary composite outcome; a univariable model with only NT-proBNP had

### Table 1. (Continued)

|               | I         | II        | III        | $P$ value | Missing (%) |
|---------------|-----------|-----------|------------|-----------|-------------|
| Hypertension (%) | 13 (13.7) | 111 (21.2) | 15 (3.9) | <0.001 | 0.0         |
| Mechanical valve (%) | 1 (1.1)  | 45 (8.6)  | 9 (2.4)   | <0.001 | 0.0         |
| Pulmonary hypertension (%) | 10 (10.5) | 23 (4.4)  | 10 (2.6)  | 0.003 | 0.0         |
| Type 2 diabetes (%) | 2 (2.1)  | 25 (4.8)  | 13 (3.4)  | 0.355 | 0.0         |
| Liver cirrhosis (%) | 0 (0.0)  | 4 (0.8)   | 20 (5.2)  | <0.001 | 0.0         |
| Chronic kidney disease (%) | 2 (2.1)  | 4 (0.8)   | 6 (1.8)   | 0.380 | 0.0         |
| Obstructive sleep apnea (%) | 9 (9.5)  | 41 (7.8)  | 29 (7.6)  | 0.829 | 0.0         |
| Cyanosis, $\text{O}_2$ saturation <92% (%) | 6 (6.8)  | 9 (1.9)   | 67 (18.7) | <0.001 | 8.1         |
| NT-proBNP, pg/mL | 78.9 [40.6, 182.2] | 113.9 [46.1, 272.3] | 173.0 [70.5, 384.8] | 0.030 | 17.2         |
| Systemic ventricular function (%) | Normal: 79 (87.8) | 380 (75.0) | 164 (47.1) | <0.001 | 5.5         |
| Borderline/mildly decreased | 9 (10.0) | 106 (20.9) | 125 (35.9) |         |             |
| Moderately/severely decreased | 2 (2.2)  | 21 (4.1)  | 59 (17.0) |         |             |

Descriptive and clinical data for the 1000 patients with anatomic and physiological classification by anatomic class. Categorical variables are presented as number (percent) and compared using Fisher exact test. Continuous variables are presented as mean (standard deviation) for normally distributed variables and as median [25th, 75th percentiles] for nonnormally distributed variables. Continuous variables are analyzed using Welch’s ANOVA. BMI indicates body mass index; CAD, coronary artery disease; CHD, congenital heart disease; DORV, double outlet right ventricle; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA FC, New York Heart Association functional class; and TGA, transposition of the great arteries.

*The category “non-White” refers to individuals with documented race other than White. This includes Black, Asian, Native American, and any other race.

with simple shunts and Eisenmenger syndrome were classified as great complexity per Bethesda, but simple per the AP classification.
Table 2. Descriptive and Clinical Characteristics of the Cohort by Physiological Stage

|                              | A                  | B                  | C                  | D                  | P value | Missing (%) |
|------------------------------|--------------------|--------------------|--------------------|--------------------|---------|-------------|
| No.                          | 57                 | 233                | 574                | 136                |         |             |
| Age, y                       | 31.0 [24.7, 38.0]  | 31.2 [24.7, 41.3]  | 35.6 [27.6, 48.4]  | 45.3 [33.5, 53.7]  | <0.001  | 0.0         |
| Sex (% women)                | 37 (64.9)          | 123 (52.8)         | 255 (44.4)         | 70 (51.5)          | 0.007   | 0.0         |
| Race (%)                     |                    |                    |                    |                    | 0.905   | 2.0         |
| Non-White                    | 3 (6.0)            | 11 (4.9)           | 36 (6.3)           | 5 (3.7)            |         |             |
| Unknown                      | 7 (14.0)           | 25 (11.1)          | 63 (11.1)          | 16 (11.9)          |         |             |
| White                        | 40 (80.0)          | 190 (84.1)         | 470 (82.6)         | 114 (84.4)         |         |             |
| BMI, kg/m²                   | 25.4 [22.6, 29.2]  | 25.4 [22.6, 29.4]  | 26.2 [23.0, 30.5]  | 25.4 [22.7, 29.3]  | 0.767   | 0.8         |
| Systolic blood pressure, mm Hg | 119.0 [113.8, 125.2] | 120.0 [112.0, 129.2] | 121.0 [111.0, 129.0] | 117.0 [107.5, 128.0] | 0.055   | 0.5         |
| Diastolic blood pressure, mm Hg | 69.5 [64.0, 73.0]  | 68.0 [61.0, 75.0]  | 68.0 [60.0, 75.0]  | 67.0 [56.5, 76.5]  | 0.054   | 0.5         |
| NYHA FC (%)                  |                    |                    |                    |                    | <0.001  | 0.0         |
| I                            | 57 (100.0)         | 202 (86.7)         | 447 (77.9)         | 53 (39.0)          |         |             |
| II                           | 0 (0.0)            | 31 (13.3)          | 111 (19.3)         | 66 (48.5)          |         |             |
| III/IV                       | 0 (0.0)            | 0 (0.0)            | 16 (2.8)           | 17 (12.5)          |         |             |
| CHD diagnosis (%)            |                    |                    |                    |                    | <0.001  | 0.0         |
| Tetralogy of Fallot          | 3 (6.3)            | 34 (14.6)          | 117 (20.4)         | 22 (16.2)          |         |             |
| Left-sided valve/ outflow tract disease (excluding coarctation) | 6 (10.5) | 37 (15.9) | 75 (13.1) | 5 (3.7) |
| Fontan                       | 2 (3.5)            | 19 (8.2)           | 85 (14.8)          | 27 (19.9)          |         |             |
| Atrial septal defect         | 9 (15.8)           | 23 (9.9)           | 35 (6.1)           | 19 (14.0)          |         |             |
| Coarctation                  | 6 (10.5)           | 32 (13.7)          | 47 (8.2)           | 4 (2.9)            |         |             |
| Atrial switch for TGA        | 2 (3.5)            | 13 (5.6)           | 37 (6.4)           | 5 (3.7)            |         |             |
| Ventricular septal defect    | 7 (12.3)           | 14 (6.0)           | 19 (3.3)           | 4 (2.9)            |         |             |
| DORV                         | 2 (3.5)            | 5 (2.1)            | 25 (4.4)           | 10 (7.4)           |         |             |
| Valvar pulmonary stenosis    | 1 (1.8)            | 7 (3.0)            | 17 (3.0)           | 3 (2.2)            |         |             |
| Arterial switch for TGA      | 1 (1.8)            | 7 (3.0)            | 20 (3.5)           | 2 (1.5)            |         |             |
| Ebstein anomaly              | 1 (1.8)            | 4 (1.7)            | 22 (3.8)           | 0 (0.0)            |         |             |
| Physiologically corrected TGA | 3 (6.3)            | 4 (1.7)            | 15 (2.6)           | 4 (2.9)            |         |             |
| Atrioventricular septal defect | 0 (0.0)            | 4 (1.7)            | 14 (2.4)           | 5 (3.7)            |         |             |
| Pulmonary atresia with intact ventricular septum | 1 (1.8) | 4 (1.7) | 12 (2.1) | 0 (0.0) |
| Eisenmenger physiology       | 0 (0.0)            | 0 (0.0)            | 0 (0.0)            | 11 (8.1)           |         |             |
| Complex cyanotic, eg, unrepaired double-inlet ventricle | 1 (1.8) | 0 (0.0) | 1 (0.2) | 6 (4.4) |
| Rastelli procedure for TGA   | 0 (0.0)            | 2 (0.9)            | 5 (0.9)            | 2 (1.5)            |         |             |
| Other                        | 12 (21.1)          | 24 (10.3)          | 28 (4.9)           | 7 (5.1)            |         |             |
| Anatomic class (%)           |                    |                    |                    |                    | <0.001  | 0.0         |
| I                            | 17 (29.8)          | 32 (13.7)          | 31 (5.4)           | 15 (11.0)          |         |             |
| II                           | 28 (45.6)          | 135 (57.9)         | 309 (53.8)         | 53 (39.0)          |         |             |
| III                          | 14 (24.6)          | 86 (28.3)          | 234 (40.8)         | 68 (50.0)          |         |             |
| Genetic syndrome (%)         | 2 (3.5)            | 17 (7.3)           | 39 (6.8)           | 11 (8.1)           | 0.709   | 0.0         |

(Continued)
a C statistic of 0.69 (95% CI, 0.67–0.71), whereas 2-variable models were slightly superior; AnatC+NT-proBNP, PhysS+NT-proBNP, and NYHA+NT-proBNP had C statistics of 0.70 (95% CI, 0.68–0.72), 0.72 (95% CI, 0.70–0.74), and 0.72 (95% CI, 0.70–0.74), respectively. The combination of AP+NT-proBNP had the highest C statistic, 0.73 (95% CI, 0.71–0.75) (Figure 3A). For all-cause mortality, the pattern was similar, though the absolute value of C statistics was consistently higher. Once again, AP+NT-proBNP had the highest C statistic, 0.85 (95% CI, 0.82–0.88). AnatC had the lowest C statistic, 0.62 (95% CI, 0.58–0.66), and was less strongly associated with mortality than was the original Bethesda classification, 0.67 (95% CI, 0.64–0.7) (Figure 3B).

Some PhyS component variables were only modestly associated with the primary outcomes, including categorical aortic dimension, with C statistics of 0.57 (95% CI, 0.55–0.59) and 0.57 (95% CI, 0.51–0.63), and valve disease with C statistics of 0.55 (95% CI, 0.53–0.57) and 0.57 (95% CI, 0.52–0.62) for the composite outcome and all-cause mortality, respectively (Figure 3C and 3D). Other continuous variables that were reasonably strongly associated with the outcomes, such as oxygen saturation, are included as dichotomous/categorical variables in the AP classification system; the derived categorical variables were consistently less able to discriminate between those who went on to suffer the composite outcome from those who did not (eg, the C statistic for continuous oxygen saturation [%] was 0.67; for the 3-level categorical variable hypoxemia [oxygen saturation <85%, 85%–90%, >90%] the C statistic was 0.57) (Figure 3C).

Interestingly, several PhyS component variables were more strongly associated with outcomes than PhyS itself (or than the overall AP classification). Arrhythmia status was the strongest predictor of the primary composite outcome (C statistic: 0.71 [95% CI, 0.69–0.73]) (Figure 3C) among the components of PhyS. History of arrhythmia and continuous resting oxygen saturation were the strongest predictors of mortality (C statistics of 0.75 [95% CI, 0.72–0.78], 0.76 [95% CI, 0.70–0.82], and 0.77 [95% CI, 0.73–0.81], respectively) (Figure 3D).

### Distribution of AP Variables

On further analysis of the reasons patients were assigned a specific PhyS, we identified the component variable most often associated with classification to a

| Component | Heart failure (%) | CAD (%) | Hypertension (%) | Mechanical valve (%) | Pulmonary hypertension (%) | Type 2 diabetes (%) | Liver cirrhosis (%) | Chronic kidney disease (%) | Obstructive sleep apnea (%) | Cyanosis, $O_2$ saturation <92% (%) | NT-proBNP, pg/mL | Systemic ventricular function (%) |
|-----------|------------------|---------|-----------------|----------------------|----------------------------|-------------------|-----------------------|-------------------------------|-----------------------------|--------------------------------|-----------------|-----------------------------|
| A         | 0 (0.0)          | 0 (0.0) | 4 (7.0)         | 4 (7.0)              | 0 (0.0)                   | 0 (0.0)           | 0 (0.0)              | 0 (0.0)                       | 1 (1.8)                     | 0 (0.0)                        | 48.5 [31.9, 103.2] | Normal                       |
| B         | 1 (0.4)          | 0 (0.0) | 32 (13.7)       | 13 (5.6)             | 0 (0.0)                   | 2 (0.9)           | 0 (0.0)              | 0 (0.0)                       | 13 (5.6)                    | 2 (0.9)                        | 90.5 [37.7, 180.3] | Borderline/mildly decreased |
| C         | 22 (3.8)         | 5 (0.9) | 83 (14.5)       | 29 (5.1)             | 10 (1.7)                  | 24 (4.2)          | 18 (3.1)             | 5 (0.9)                       | 47 (8.2)                    | 44 (8.3)                       | 135.8 [35.7, 314.6] | Moderately/severely decreased |
| D         | 17 (12.5)        | 2 (1.5) | 20 (14.7)       | 9 (6.6)              | 33 (24.3)                 | 14 (10.3)         | 6 (4.4)              | 7 (5.1)                       | 18 (13.2)                   | 36 (29.8)                      | 372.7 [150.0, 956.5] |                         |
| P value   | <0.001           | 0.328   | 0.478           | 0.849                | <0.001                    | <0.001            | 0.013                 | <0.001                        | 0.018                       | <0.001                        | 0.001            | 5.5                         |
| Missing (%) | 0.0              | 0.0     | 0.0             | 0.0                  | 0.0                       | 0.0               | 0.0                  | 0.0                           | 0.0                         | 8.1                            | 17.2             | 5.5                         |

Descriptive and clinical data for the 1000 patients with anatomic and physiological classification by physiological stage. Categorical variables are presented as number (percent) and compared using Fisher exact test. Continuous variables are presented as mean (standard deviation) for normally distributed variables and as median (25th, 75th percentiles) for nonnormally distributed variables. Continuous variables are analyzed using Welch’s ANOVA. BMI indicates body mass index; CAD, coronary artery disease; CHD, congenital heart disease; DORV, double outlet right ventricle; NT-proBNP, N-terminal proB-type natriuretic peptide; NYHA FC, New York Heart Association functional class; and TGA, transposition of the great arteries. The category “non-White” refers to individuals with documented race other than White. This includes Black, Asian, Native American, and any other race.
Figure 1. Kaplan-Meier curves depicting survival free from a composite clinical outcome of death or nonelective cardiovascular hospitalization according to anatomic class and physiological stage. Kaplan-Meier curves of survival free of the composite outcome by (A) anatomic class and (B) physiological stage. Curves are compared using the log-rank test. Shaded regions indicate 95% CIs.
worse PhyS (ie, if all other variables indicated a less severe PhyS) (Figure 4). For example, 96 patients were classified as PhyS C rather than PhyS B only because of qualifying valve disease, and 68 were classified as PhyS C only because of a maximal aortic dimension of 4.0 to 4.9 cm (Figure 4).

**DISCUSSION**

In this analysis of the AP classification system proposed in the 2018 American Heart Association and American College of Cardiology ACHD guidelines, we report that: (1) PhyS adds discriminative prognostic value to anatomic diagnosis-focused classification systems, but its overall prognostic value is limited by including variables relevant to clinical care but not associated with prognosis. (2) AP classification is associated with future mortality, and to a lesser degree, nonelective hospitalization of patients with ACHD. (3) The AP system is similarly associated with clinical outcomes as other individual variables and simple multivariable approaches.
ACHD poses a challenge to straightforward classification.\textsuperscript{20,21} There are numerous distinct diseases, interventions, and comorbidities.\textsuperscript{22,23} Each of these may impact the probability of suffering an adverse outcome, with variability between diagnoses.\textsuperscript{20} Although ACHD classification has traditionally focused on underlying CHD anatomic diagnosis, this approach is not well-suited to identifying the change in risk over time.\textsuperscript{20,21} Past studies of risk-stratification in the ACHD population are limited to short-term or surgical outcomes or focus on specific disease subsets.\textsuperscript{24–26} Other studies have focused on identifying risk factors across the ACHD population, but this is difficult to apply to a heterogeneous population, with generalizability undermined by the local referral patterns and the variable approach to management between different countries and between centers within the same country.\textsuperscript{20,21,27} The AP system is the first effort to use both anatomic and physiologic variables to offer individualized risk stratification for all patients with ACHD.

The current study design parallels other work evaluating similar, multidimensional classification systems, such as cancer grading/staging.\textsuperscript{28–30} Two recent studies have assessed the prognostic and discriminative value of the ACHD AP classification system.\textsuperscript{9,10} One retrospectively assessed the association between the AP system and 15-year all-cause and cardiovascular mortality; as with the current study, the C statistics indicated good discrimination, but other clinical models were superior.\textsuperscript{9} The second study found the AP system to be strongly associated with early mortality after cardiovascular surgery.\textsuperscript{10} The current study is the first to assess not only mortality but also more common clinically relevant outcomes (nonelective cardiovascular hospitalization) and to assess this model in a
Table 3. Hazard Ratios for the Primary and Secondary Outcomes According to the Anatomic and Physiological Classification

| No. events | All-cause mortality or nonelective cardiovascular hospitalization | All-cause mortality | New/worsening heart failure | Arrhythmia |
|------------|---------------------------------------------------------------|---------------------|-----------------------------|------------|
|            | No. events n/N (%)                                           | n/N (%)             | HR                          | P value    | HR                          | P value    | HR                          | P value |
| IIA        | IA 1/17 (5.9) 0.78 0.802 0.0%                                 | 0/17 (0.0)          | ...                         | ...        | 0/17 (0.0)                  | ...        | 1/17 (5.9)                  | 0.72 0.748 |
|            | IB 2/32 (6.3) 0.56 0.419 0.0%                                 | 0/32 (0.0)          | ...                         | ...        | 1/32 (3.1)                  | 0.27 0.197 | 2/32 (6.3)                  | 0.63 0.519 |
|            | IC 2/31 (6.5) 0.62 0.514 1.92 0.542 4/31 (12.9)              | 1/31 (3.2)          | ...                         | ...        | 4/31 (12.9)                 | 1.23 0.695 | 3/31 (9.7)                  | 1.18 0.783 |
|            | ID 3/15 (20.0) 1.42 0.560 3.23 0.274 4/15 (26.7)             | 1/15 (6.7)          | ...                         | ...        | 1/15 (6.7)                 | 0.36 0.006 | 4/15 (26.7)                 | 1.97 0.259 |
|            | IIA 1/26 (3.9) 0.28 0.211 0.26 0.0%                           | 0/26 (0.0)          | ...                         | ...        | 0/26 (0.0)                  | ...        | 0/26 (0.0)                  | ...        |
|            | IIB 8/135 (5.9) 0.42 0.02* 0.135 (0.0)                        | 4/135 (3.1)         | 0.22 0.004*                 | 5/135 (3.7) | 0.32 0.016*                | Reference  |
|            | IIC 44/309 (14.2) Reference                                  | 7/309 (2.3)         | Reference                   | 39/309 (12.6) | Reference                   | 35/309 (11.3) | Reference |
|            | IIA 1/26 (3.9) 0.28 0.211 0.26 0.0%                           | 0/26 (0.0)          | ...                         | ...        | 0/26 (0.0)                  | ...        | 0/26 (0.0)                  | ...        |
|            | IIB 6/66 (9.1) 0.58 0.026 0.66 (0.0)                          | 4/66 (6.1)          | 0.42 0.099                  | 8/66 (12.1) | 0.99 0.986                 | Reference  |
|            | IIC 57/234 (24.4) 1.58 0.02* 12/234 (5.1)                    | 1.81 0.215          | 4/1234 (20.1)               | 1.49 0.068 | 41/234 (17.5)               | 1.44 0.111 |
|            | IIA 38/185 (55.9) 4.46 <0.0001* 18/185 (26.5)                | 10.11 <0.0001*     | 29/185 (42.6)               | 3.69 <0.0001* | 25/185 (42.6)               | 4.16 <0.0001* |
|            | IIB 23/185 (55.9) 0.69 (0.67–0.71)                            | 0.81 (0.78–0.84)    | 0.70 (0.68–0.72)            | 1.17 (1.09–1.25) | 0.89 (0.85–0.93)           | 0.69 (0.67–0.71) |

*P* <0.05.
prospectively enrolled cohort. Additionally, the current cohort includes patients with more complex CHD and worse functional status than those used in these other studies; over 13% (n=136) of patients in the current cohort were categorized as Phys D, compared with 3% (n=19/629) and 6% (n=22/353) in prior studies; only 17 patients in the prior studies combined were classified as IIID, compared with 69 in the current report. This, along with the larger overall sample size, allowed us to explore in more detail how individual component variables contributed to AP classification and prognostic value.

Predicting prognosis was not the goal of the 2018 AHA/ACC ACHD guidelines or the proposed AP classification scheme; these guidelines are primarily designed to guide cardiovascular care and timing of follow-up for patients with ACHD with a broad array of diagnoses and subsequent interventions. Decisions in that context usually focus on predicted probability of adverse events ≈3 months to ≈3 years in the future. Therefore, this near-term and medium-term prediction of clinical risk are most relevant when considering the value of the AP system. The PhyS system is more reflective of a patient’s functional status and overall health than AnatC in isolation, which could classify a patient with ASD and Eisenmenger syndrome as simple. Although it is clear that PhyS adds predictive value beyond anatomic classification, it also intermingles variables that have broad prognostic implications (eg, functional class) with others that have follow-up relevance for only a subset of patients (eg, aortic dimension). Prognosis is an important consideration when determining appropriate follow-up, but so are other variables, independent of their impact on prognosis. It may be reasonable to separate those roles in future iterations of this classification scheme. That is, the decision about frequency of evaluations may change if either there was an indication of a high risk of deterioration in the near to medium term, or if there were particular clinical characteristics that may compel intervention. With this in mind, we identified other individual variables that were more strongly associated with prognosis across the range of outcomes compared with the AP classification. These included
circulating biomarkers (NT-proBNP), clinical history (prior atrial arrhythmia), and simple assessments of functional class (NYHA FC).

Another notable finding was the exceptionally uneven distribution of AP class, for example, with few patients in this cohort classified as PhyS A. Our results suggest little difference in terms of prognosis between PhyS A and B, and perhaps combining these stages would both simplify and strengthen the AP system. Furthermore, patients with a broad range of disease phenotypes can be categorized in the same PhyS. For example, a patient who is NYHA FC III is assigned the same PhyS as a patient with moderate pulmonary regurgitation. Revisiting the dichotomization/categorization of continuous variables and their relationship to cardiovascular care, as well as reducing the heterogeneity within each PhyS, could help improve the prognostic power of the AP system.

It may seem surprising that the Bethesda classification of CHD was more strongly associated with outcomes than the more recently developed AnatC. One possible explanation is the divergent classification of congenital aortic valve disease. The Bethesda classification assigned bicuspid aortic valve to simple complexity CHD, whereas these patients are AnatC II (moderate complexity) in the AP system. AnatC also focuses more on underlying anatomy rather than physiology. For example, Eisenmenger syndrome is considered severely complex by the Bethesda criteria, whereas a patient with Eisenmenger syndrome could be classified as AnatC I or II (eg, small atrial septal defect with Qp:Qs<1.5:1 and without chamber enlargement). The presence of pulmonary vascular disease does not directly influence AnatC, emphasizing the importance of interpreting AnatC in concert with PhyS.

This study identified several aspects of the AP classification that might benefit from reconsideration. For example, including continuous variables rather than categorical variables with arbitrary cut points would improve the association with clinical outcomes. Likewise, it could be helpful to integrate quantitative biomarkers, such as NT-proBNP or C-reactive protein, which are easily measured and associated with clinical outcomes across the spectrum of ACHD. Inclusion of such biomarkers could be accomplished through the use of risk scores, such as have been developed for atherosclerotic cardiovascular disease.

Limitations

This study must be interpreted in the context of its study design. AP classification was assigned based on information available in the electronic health record. Prospective assessment of AP class may be more accurate and reproducible particularly for PhyS, though there is currently no empirical evidence to suggest that. Additionally, classifying patients required defining more detailed criteria than provided in the AP guidelines; there may be alternative interpretations that could be more strongly associated with outcomes, though our definitions were based on a consensus of an expert panel, including several authors of the existing guidelines. It is important to note that the BACH enrolls patients at a referral center, and enrollment at the time of clinical visit may be more likely to include sicker patients, because those patients are likely to be seen more frequently. This may limit our ability to assess the AP system’s performance in subjects with simpler, less severe CHD (eg, IA). From a statistical standpoint, the methods for comparing C statistics are limited, unsettled, and controversial. This limited our ability to compare the different models quantitatively. Finally, we did not aim to derive the most robust predictive model but rather to understand better the predictive value of the AP classification relative to its component variables and other straightforward 1- and 2-variable models. We do not propose any of the models described in this analysis as the preferred approach to predicting future events in ACHD.

CONCLUSIONS

This study has fundamental implications for the application of the ACHD AP system to clinical practice. Future versions of the AP system could include risk scores or nomograms, which would better capture the heterogeneity of this population. Our results suggest that incorporating multiple individual continuous variables, rather than a summary category, retains important prognostic information; the AP system might be improved by reconsidering categorizations and incorporating additional variables. Although this is a first step toward personalizing ACHD care, the prognostic performance of the AP system may not offer an advantage beyond existing, simpler approaches.

**Sources of Funding**

This work was conducted with support from Harvard Catalyst/Thοe Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award UL1 TR001102), and financial contributions from Harvard University and its affiliated academic healthcare centers. The content is solely the authors’ responsibility and does not necessarily
represent the official views of Harvard Catalyst, Harvard University and its affiliated academic healthcare centers, or the National Institutes of Health. Dr Lachtrupp was funded by the Harvard Medical School Scholars in Medicine Office. Dr Valente was supported by the Sarah Marie Llamos Fund for Adult Congenital Heart Disease Research. Dr Opotowsky was supported by the Cincinnati Children’s Hospital Heart Institute Research Core (HIRC). Drs Gurvitz, Landzberg, Opotowsky, Valente, and Wu were supported by the Dunlevie Family Fund.

Disclosures
None.

Supplementary Material
Tables S1–S5
Figure S1

REFERENCES
1. Willems R, Werbrouck A, De Backer J, Annemans L. Real-world health-care utilization in adult congenital heart disease: a systematic review of trends and ratios. Cardiol Young. 2019;29:553–563. DOI: 10.1017/S1047951119000441.
2. Gilboa SM, Devine OJ, Kucik JE, Oster ME, Riehle-Colarusso T, SB, Opotowsky AR. Interobserver agreement of the anatomic and physiological classification in adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2008;118:e714–e833. DOI: 10.1161/CIRCULATIONAHA.108.190690.
3. Dimopoulos K, Diller G-P, Katsiada E, Pijuan-Domenesch A, Papadopoulos SA, Babu-Narayan SV, Salutke TV, Piepoli MF, Poole-Wilson PA, Best N, et al. Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart disease. Circulation. 2014;130:749–756. DOI: 10.1161/CIRCULATIONAHA.113.038936.
4. O’Leary JM, Siddiqi OK, de Ferranti S, Landzberg MJ, Opotowsky AR. The changing demographics of congenital heart disease hospitalizations in the United States, 1998 through 2016. JAMA. 2013;309:884–896. DOI: 10.1001/jama.2013.584.
5. Wernly B, Lichtenauer M, Franz M, Kabisch B, Muessig J, Masyuk M, Hoppe UC, Kelm M, Jung C. Model for End-stage Liver Disease excluding INR (MELD-xl) score critically ill patients: easily available and of prognostic relevance. PLoS One. 2012;1:e1070987. DOI: 10.1371/journal.pone.01070987.
6. Lachtrupp CL, Valente AM, Gurvitz M, Landzberg MJ, Brindard SB, Opotowsky AR. Interobserver agreement of the anatomic and physiological classification system for adult congenital heart disease. Am Heart J. 2020;229:92–99. DOI: 10.1016/j.ahj.2020.07.013.
7. Camm AJ, Savelieva I, Lip GYH. Rate control in the medical management of atrial fibrillation. Heart. 2007;93:35–38. DOI: 10.1136/hrt.2006.099903.
8. Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani A, Agarwal A, Dudley CW, Nah G, Hayward R, Tseng ZH. Clinical outcomes during admissions for heart failure among adults with congenital heart disease. J Am Coll Cardiol. 2013;61:1432–1440. DOI: 10.1016/j.jcc.2012.12.142.
9. van Buuren S, Groothuis-Oudshoorn K. mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45:1–67.
10. Gilboa SM, Devine OJ, Kucik JE, Oster ME, Riehle-Colarusso T, SB, Opotowsky AR. Interobserver agreement of the anatomic and physiological classification in adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease: developed in collaboration with the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2008;118:e714–e833. DOI: 10.1161/CIRCULATIONAHA.108.190690.
11. Dimopoulos K, Diller G-P, Katsiada E, Pijuan-Domenesch A, Papadopoulos SA, Babu-Narayan SV, Salutke TV, Piepoli MF, Poole-Wilson PA, Best N, et al. Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart disease. Circulation. 2014;130:749–756. DOI: 10.1161/CIRCULATIONAHA.113.038936.
12. Lachtrupp et al. ACHD Anatomic Physiological Class and Prognosis

J Am Heart Assoc. 2021;10:e021345. DOI: 10.1161/JAHA.120.021345

14
29. Morita S, Mizumachi T, Nakamatu Y, Sakashita T, Kano S, Hoshino K, Fukuda A, Fujiiwa K, Homma A. Comparison of the University of Pittsburgh staging system and the eighth edition of the American Joint Committee on Cancer TNM classification for the prognostic evaluation of external auditory canal cancer. *Int J Clin Oncol*. 2018;23:1029–1037. DOI: 10.1007/s10147-018-1314-3.

30. Weiss A, Chavez-Macgregor M, Lichtensztajn DY, Yi M, Tadros A, Hoftsagayi GN, Giordano SH, Hunt KK, Mittendorf EA. Validation study of the American Joint Committee on Cancer eighth edition prognostic stage compared with the anatomic stage in breast cancer. *JAMA Oncol*. 2018;4:203–209. DOI: 10.1001/jamaoncol.2017.4298.

31. Baggen VJ, van den Bosch AE, Eindhoven JA, Schut A-R, Cuypers JAAE, Witsenburg M, de Waart M, van Schaik RHN, Zijlstra F, Boersma E, et al. Prognostic value of N-terminal pro-B-type natriuretic peptide, troponin-T, and growth-differentiation factor 15 in adult congenital heart disease. *Circulation*. 2017;135:264–279. DOI: 10.1161/CIRCULATIONAHA.116.023255.

32. Opotowsky AR, Valente AM, Alshawabkeh L, Cheng S, Bradley A, Rimm EB, Landzberg MJ. Prospective cohort study of C-reactive protein as a predictor of clinical events in adults with congenital heart disease: results of the Boston adult congenital heart disease biobank. *Eur Heart J*. 2018;39:3253–3261. DOI: 10.1093/eurheartj/ehy362.

33. Baggen VJM, Venema E, Živná R, van den Bosch AE, Eindhoven JA, Witsenburg M, Cuypers JAAE, Boersma E, Linghsma H, Popelová JR, et al. Development and validation of a risk prediction model in patients with adult congenital heart disease. *Int J Cardiol*. 2019;276:87–92. DOI: 10.1016/j.ijcard.2018.08.059.

34. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O’Donnell CJ, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. *Circulation*. 2014;129:S49–S73. DOI: 10.1161/01.cir.0000437741.48606.98.

35. Han X, Zhang Y, Shao Y. On comparing two correlated C indices with censored survival data. *Stat Med*. 2017;36:4041–4049.
SUPPLEMENTAL MATERIAL
Table S1. Criteria used to assign anatomic class: simple, moderate complexity, or great complexity.

| I: Simple | Consensus Criteria Used | ACC/AHA Guidelines |
|-----------|-------------------------|--------------------|
| **Native disease** | | |
| **Isolated small ASD** | Isolated secundum ASD, excluding primum ASD and sinus venosus. Qp:Qs < 1.5:1 and no chamber enlargement distal to the shunt defined as subjectively enlarged or Z score > +2 for quantitative measurement (e.g., cMR) | An intracardiac shunt not meeting these criteria (Qp:Qs ≥1.5:1, chamber enlargement distal to the shunt) would be described as small or trivial |
| **Isolated small VSD** | Isolated VSD for which Qp:Qs is < 1.5:1 and there is no chamber enlargement distal to the shunt defined as mild subjectively or Z score > +2 for quantitative measurement (e.g., cMR) | An intracardiac shunt not meeting these criteria (Qp:Qs ≥1.5:1, chamber enlargement distal to the shunt) would be described as small or trivial |
| **Mild isolated pulmonic stenosis** | TTE peak gradient < 36mmHg (velocity < 3m/s) if reported; otherwise "mild" by subjective imaging report; mild to moderate in TTE report without reported gradient = mild pulmonary stenosis | Peak gradient < 36 mm Hg (peak velocity < 3 m/s) |
| **Repaired conditions** | | |
| **Previously ligated or occluded ductus arteriosus** | | No Comment |
| **Repaired secundum ASD or sinus venous defect without significant residual shunt or chamber enlargement** | Significant shunt defined as ≥1.5:1; chamber enlargement defined as mild+ subjectively, Z score > +2 for quantitative measurement (e.g., cMR) | Significant shunt is Qp:Qs≥1.5:1 |
| **Repaired VSD without significant residual shunt or chamber enlargement** | Significant shunt defined as ≥1.5:1; chamber enlargement defined as mild+ subjectively, Z score > +2 for quantitative measurement (e.g., cMR) | Significant shunt is Qp:Qs≥1.5:1 |
| **Vascular ring** | | Not mentioned |

II: Moderate Complexity

| Consensus Criteria Used | ACC/AHA Guidelines |
|-------------------------|--------------------|
| | |


| Condition                                                                 | Comment                                      |
|--------------------------------------------------------------------------|----------------------------------------------|
| Aorto-left ventricular fistula                                            | No Comment                                  |
| Anomalous pulmonary venous connection, partial or total                  | No Comment                                  |
| Anomalous coronary artery arising from the pulmonary artery              | No Comment                                  |
| Anomalous aortic origin of a coronary artery from the opposite sinus     | No Comment                                  |
| AVSD (partial or complete, including primum ASD)                         | No Comment                                  |
| Congenital aortic valve disease                                          | No Comment                                  |
| Congenital mitral valve disease                                          | Excluding mitral valve prolapse              |
| Coarctation of the aorta                                                | No Comment                                  |
| Ebstein anomaly (mild, moderate, and severe)                             | No Comment                                  |
| Infundibular right ventricular outflow obstruction                       | No Comment                                  |
| Ostium primum ASD                                                        | No Comment                                  |
| Moderate and large unrepaird secundum ASD                                | No Comment                                  |
| Moderate and large persistently patent ductus arteriosus                 | No Comment                                  |
| Pulmonary valve regurgitation (moderate or greater)                      | Regurgitant fraction ≥20% (cMR) and/or ≥moderate (TTE) No Comment |
| Pulmonary valve stenosis (moderate or greater)                           | Peak gradient ≥ 36mmHg (velocity ≥3 m/s) or subjectively ≥ moderate ≥Moderate RVOT obstruction (≥36 mmHg (peak velocity ≥3 m/s)) No Comment |
| Peripheral pulmonary stenosis                                            | No Comment                                  |
| Sinus of Valsalva fistula/aneurysm                                       | No Comment                                  |
| Sinus venosus defect                                                     | No Comment                                  |
| Subvalvar aortic stenosis (excluding HCM)                                | No Comment                                  |
| Supravalvar aortic stenosis                                              | No Comment                                  |
| Straddling AV valve                                                      | No Comment                                  |
| Repaired tetralogy of Fallot (toF)                                       | Repaired toF, without pulmonary atresia No Comment |
| VSD with associated abnormality and/or moderate or greater shunt         | VSD & ≥ moderate shunt (Qp:Qs≥1.5:1) or chamber enlargement (≥mild subjectively or Z score >+2) An intracardiac shunt is hemodynamically significant if: there is chamber enlargement distal to the shunt or Qp:Qs≥1.5:1. |
| Double-chambered Right Ventricle                                         | Not mentioned                               |
| Cor triatriatum                                                          |                                              |

### III: Great Complexity (or Complex)

| Condition                                                                 | Consensus Criteria Used | ACC/AHA Guidelines |
|--------------------------------------------------------------------------|-------------------------|--------------------|
| Cyanotic congenital heart defect (unrepaired or palliated, all forms)   | No Comment              |                    |
| Diagnosis                                                                 | Clarification                              | Comment       |
|--------------------------------------------------------------------------|--------------------------------------------|---------------|
| Double-outlet ventricle                                                  |                                            | No Comment    |
| Fontan procedure                                                         |                                            | No Comment    |
| Interrupted aortic arch                                                  |                                            | No Comment    |
| Mitral atresia                                                           |                                            | No Comment    |
| Single ventricle (including double inlet left ventricle, tricuspid atresia, hypoplastic left heart, any other anatomic abnormality with a functionally single ventricle) |                                            | No Comment    |
| Pulmonary atresia (all forms)                                            | Includes repaired or unrepaired PA/IVS or toF/PA | No Comment    |
| TGA (classic or d-TGA; CCTGA or l-TGA)                                   |                                            | No Comment    |
| Truncus arteriosus                                                       |                                            | No Comment    |
| Other abnormalities of atrioventricular and ventriculoarterial connection (i.e., crisscross heart, isomerism, heterotaxy syndromes, ventricular inversion) |                                            | No Comment    |

Categorization and wording of the diagnoses listed are taken from the ACC/AHA guidelines. In cases where there might be ambiguity (e.g., does mitral valve prolapse qualify as “congenital mitral valve disease”), further clarification of the definitions used in classification is listed. Diagnoses omitted from the guidelines were classified according to expert opinion. Unless otherwise specified, a diagnosis recorded consistently in clinical notes and testing was used to define specific diagnoses.

ASD = atrial septal defect, AV = atrio-ventricular, AVSD = atrio-ventricular septal defect, CHD = congenital heart disease, cMR = cardiac magnetic resonance, HCM = hypertrophic cardiomyopathy, IVS = intact ventricular septum, PA = pulmonary atresia, PS = pulmonary stenosis, RVOT = right ventricular outflow tract, toF = tetralogy of Fallot, TGA = transposition of the great arteries (cc = congenitally/physiologically corrected), TTE = trans-thoracic echocardiograph, VSD = ventricular septal defect
Table S2. Consensus criteria use to assign ACC/AHA physiological stage: A, B, C, or D.

| Stage A | Consensus Criteria Used                                                                                                                                                                                                                                                                                                                                 | ACC/AHA Guidelines                                                                 |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| **NYHA FC I symptoms** | Cardiac disease with no limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitations, dyspnea, or anginal pain.                                                                                                                                       | No Comment                                                                         |
| **No hemodynamic or anatomic sequelae** | This may vary by diagnosis and includes the absence of: ventricular dilation/dysfunction, heart failure, aortic enlargement, systemic hypertension in aortic coarctation (resting blood pressure ≥ 130/80), and pulmonary hypertension.                                                                                                                | No Comment                                                                         |
| **No arrhythmias** | No clinically relevant arrhythmia other than asymptomatic isolated PACs/PVCs. This excludes any arrhythmia leading to therapy including medication, ablation, cardioversion, emergency room visit, or hospitalization in prior 24 months. Isolated PACs/PVCs (e.g., causing palpitations or lightheadedness) would not be considered a clinically relevant arrhythmia. | No documented clinically relevant atrial or ventricular tachyarrhythmias            |
| **Normal exercise capacity** | Peak VO$_2$ ≥85% of the mean value for their diagnostic group$^{17}$                                                                                                                                                                                                                                                                                      | Abnormal: exercise maximum ventilatory equivalent of oxygen* below the range expected for the specific CHD anatomic diagnosis. |
| **Normal renal, hepatic, and pulmonary function** | No restrictive or obstructive lung disease (i.e., FVC>80% predicted); no liver abnormality on imaging or exam, no splenomegaly, MELD-XI score ≤ 12$^{14,15}$, normal albumin; eGFR >60$^{16}$                                                                                                                                 | No Comment                                                                         |
| Stage B                          | Consensus Criteria Used                                                                                                                                                                                                 | ACC/AHA Guidelines                                                                 |
|---------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| NYHA FC II symptoms             | Cardiac disease resulting in slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain                                                                 | No Comment                                                                       |
| **Mild hemodynamic sequelae**   | Mild sub-pulmonary/sub-systemic ventricular dysfunction (LVEF 40-50% and/or RVEF 35-45%, per Boston Children’s Hospital protocol), mild aortic enlargement (maximum diameter 3.5-3.9 cm), mild sub-systemic/sub-pulmonary ventricular enlargement (per imaging report) on imaging or testing from the prior 5 years. | Mild aortic enlargement (maximum diameter 3.5-3.9 cm)                             |
| **Mild valvular disease**       | Mild AS/AR/MS/MR/TS (per imaging report). This will not include mild PR or TR as these can be found in healthy patients.                                                                                               | No Comment                                                                       |
| **Trivial or small shunt**      | No evidence of chamber enlargement distal to the shunt (TTE report of Z score > +2 per cMR), Qp:Qs<1.5:1                                                                                                                | No evidence of chamber enlargement distal to the shunt, Qp:Qs<1.5:1              |
| **Arrhythmia not requiring**    | Clinically relevant arrhythmia (including atrial or ventricular tachyarrhythmia, bradyarrhythmia with HR <50) in prior 24 months not treated with medication currently (including antiarrhythmic medication or digoxin for the purpose of suppressing arrhythmia) or ablation or cardioversion > 24 months prior without further clinically apparent arrhythmia. Clinically relevant will exclude PACs/PVCs. | Bradyarrhythmia, atrial or ventricular tachyarrhythmia not requiring antiarrhythmic therapy, cardioversion, or ablation |
| **Abnormal objective cardiac**  | Peak VO₂<85% of the mean value for that diagnostic group^{17}                                                                                                                                                           | Exercise maximum ventilatory equivalent of oxygen below the range expected for specific CHD anatomic diagnosis |
| Stage C | Consensus Criteria Used | ACC/AHA Guidelines |
|---------|-------------------------|---------------------|
| NYHA FC III symptoms | Cardiac disease resulting in marked limitation of physical activity. Comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation, dyspnea, or anginal pain | No Comment |
| Significant (≥ moderate) valvular disease; ≥moderate ventricular dysfunction (systemic and/or sub-pulmonic) | ≥Moderate grade of any valve dysfunction (imaging report); ≥moderate reduction in sub-systemic or sub-pulmonary ventricular function (LVEF < 40% and/or RVEF <35%, per Boston Children’s Hospital protocol) on imaging/testing. From the prior 5 years. | No Comment |
| Moderate aortic enlargement | Per guidelines | Moderate aortic enlargement defined as maximum diameter 4.0-4.9cm |
| Venous or arterial stenosis | Per guidelines | Re-coarctation after CoA repair, supravalvular aortic obstruction, venous baffle obstruction, supravalvular pulmonary, branch PA stenosis, stenosis of cavo-pulmonary connection, pulmonary vein stenosis |
| Mild or moderate hypoxemia/cyanosis | Per guidelines, with O₂ saturation ≤90% and >85% | Hypoxemia is defined as oxygen saturation measured by pulse oximetry ≤ 90% |
| Hemodynamically significant shunt | Evidence of chamber enlargement distal to shunt (imaging report or Z score > +2 on cMR) and/or evidence of sustained Qp:Qs ≥1.5:1 | Evidence of chamber enlargement distal to shunt and/or evidence of sustained Qp:Qs ≥1.5:1 |
| Arrhythmias controlled with treatment | Clinically relevant arrhythmia in prior 24 months treated with medication currently (including anti-arrhythmic medication, digoxin for the purpose of suppressing arrhythmia), ablation in prior 24 months without further clinical arrhythmia, cardioversion in prior 24 months, ICD, pacemaker dependent | Bradyarrhythmia requiring PPM; atrial or ventricular tachyarrhythmia requiring antiarrhythmic therapy, cardioversion, or ablation; AF and controlled ventricular response; patients with ICD |
for high grade conduction disease or to maintain HR > 50 bpm.
Rate control target for tachyarrhythmias 90-115 w/ exercise/anaerobic threshold, 60-80 at rest\textsuperscript{17}

| Pulmonary hypertension (less than severe) | PA pressure by right heart catheterization $\geq 25$ mmHg and not currently requiring treatment | Mean PA pressure by right heart catheterization $\geq 25$ mmHg. |
|------------------------------------------|---------------------------------------------------------------------------------------------|--------------------------------------------------|
| **End-organ dysfunction responsive to therapy** | Organ dysfunction responsive to therapy that directly stems from their cardiac disease or treatment, or which may otherwise impact cardiovascular care, including: eGFR 30-60\textsuperscript{16}, moderate restrictive lung disease (FVC 50-70\% predicted), cirrhosis with albumin concentration $\geq 3$ g/dL or MELD-XI score $\leq 12$\textsuperscript{14,15} with therapy to improve cardiac output/reduce fluid overload, protein losing enteropathy w/ albumin $\geq 3$ | No Comment |
| Stage D | Consensus Criteria Used | ACC/AHA Guidelines |
|---------|------------------------|--------------------|
| NYHA FC IV symptoms | Cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or anginal syndrome may be present at rest. Physical activity increases discomfort. | No Comment |
| Severe aortic enlargement | Per guidelines, relating to dilation at any level of aorta | Severe aortic enlargement is defined as maximum diameter ≥ 5.0cm |
| Arrhythmia refractory to treatment | Clinically relevant arrhythmia including symptomatic bradyarrhythmia and atrial or ventricular tachyarrhythmias, in the prior 24 months with continued arrhythmia despite medical therapy (including anti arrhythmic medication or digoxin for the purpose of suppressing arrhythmia), ablation, or cardioversion. Rate control goals for tachyarrhythmia are 60-80 at rest and 90-115 with exercise and at maximal exertion | Atrial or ventricular tachyarrhythmia currently unresponsive to or refractory to antiarrhythmic therapy or ablation |
| Severe hypoxemia (almost always associated with cyanosis) | Per guidelines | Severe hypoxemia is defined as oxygen saturation at rest <85% |
| Severe pulmonary hypertension | Mean pulmonary arterial pressure ≥35 mm Hg diagnosis confirmed by right heart catheterization (limited primary sources define PH by severity); or treatment for PH/PAH | No Comment |
| Eisenmenger syndrome | Presence of right-to-left shunt (Qp:Qs <1) and elevated pulmonary pressures | No Comment |
| Refractory end-organ dysfunction | On dialysis, eGFR<30, severe restrictive lung disease (FVC <50% predicted), cirrhosis with albumin <3 and/or MELD-XI score >12 despite therapy to improve cardiac output/reduce fluid overload, protein losing enteropathy with albumin <3, or other severe end organ dysfunction directly or indirectly related to congenital heart disease (i.e., caused by or exacerbating the clinical course of CHD) | No Comment |

Consensus definitions used in assignment of physiological stage, as defined by the ACC/AHA guidelines and with additional information from expert opinion and the literature when additional definition was needed. AR = aortic regurgitation, AS = aortic stenosis, CHD = congenital heart disease, cMR = cardiac magnetic resonance, eGFR = estimated glomerular filtration rate, FEV1 = forced expiratory volume in one second, FVC = forced vital capacity, HR = heart rate, MR = mitral regurgitation, MS = mitral...
stenosis, NYHA FC = New York Heart Association functional class, PA = pulmonary artery, PAC = premature atrial complexes, PAH = pulmonary arterial hypertension, PH = pulmonary hypertension, PR = pulmonary regurgitation, PS = pulmonary stenosis, PVC = premature ventricular complexes, Qp:Qs = pulmonary flow:systemic flow, TR = tricuspid regurgitation, TS = tricuspid stenosis, TTE = trans-thoracic echocardiography, VO$_2$ = oxygen uptake

*The 2018 ACC/AHA guideline refers to “ventilatory equivalent for oxygen”, a term indicating the relationship between minute ventilation and oxygen consumption (VE:VO$_2$). Based on context and confirmed in discussion with several authors of those guidelines, this was a typo and was intended to refer to peak oxygen consumption or uptake (VO$_2$).
Table S3. Variables used for imputation of NT-proBNP, using multiple imputation by chained equations.

| Variable                                                      | Missing (%) | Variable                                                      | Missing (%) |
|---------------------------------------------------------------|-------------|---------------------------------------------------------------|-------------|
| Sex                                                           | 0.0         | Log<sub>2</sub> area deprivation index, national rank         | 3.4         |
| Anatomic complexity                                           | 0.0         | Log<sub>2</sub> area deprivation index, state rank            | 3.4         |
| Physiological stage                                           | 0.0         | Race                                                         | 1.7         |
| Anatomic and physiological class                              | 0.0         | Heart failure                                                | 0.0         |
| Death or non-elective cardiovascular hospitalization          | 0.0         | Any cardiopulmonary medications                              | 0.0         |
| Time, death or nonelective hospitalization                    | 0.0         | Number cardiopulmonary medications                           | 0.0         |
| Vital status at last follow-up                                | 0.0         | BMI, kg/m<sup>2</sup>                                         | 0.8         |
| Time until last follow-up or death                            | 0.0         | Log<sub>2</sub> peak VO<sub>2</sub>, % predicted              | 31.7        |
| Composite primary outcome at one year                         | 0.0         | Arrhythmia event                                             | 0.0         |
| Log<sub>2</sub> NT-proBNP                                     | 17.2        | Bleeding event                                               | 0.0         |
| Log<sub>2</sub> CRP                                           | 5.5         | Heart failure event                                          | 0.0         |
| Log<sub>2</sub> glucose                                      | 5.1         | Catheter/surgical intervention                               | 0.0         |
| Log<sub>2</sub> triglycerides                                 | 5.2         | Thromboembolic event                                         | 0.0         |
| NYHA FC                                                       | 0.0         | Age                                                          | 0.0         |
| Bethesda classification, CHD severity                         | 1.7         | Any psychiatric diagnosis                                    | 0.0         |
| Education, grade completed                                    | 15.7        | Number of procedures                                         | 2.0         |
| Fulltime employment                                           | 6.2         | CAD                                                          | 0.0         |
| Systemic ventricular function, %                              | 0.2         | Type 2 DM                                                    | 0.0         |

NT-proBNP was imputed with multiple imputation by chained equations, with 20 imputed data sets.

BMI = body mass index, CAD = coronary artery disease, CHD = congenital heart disease, CRP = C-reactive protein, DM = diabetes mellitus, NYHA FC = New York Heart Association functional class
Table S4. Comparison of those with and without NT-proBNP, among the 1,000 enrollees in the cohort with follow-up data.

|                        | Yes          | No           | P value | Missing (%) |
|------------------------|--------------|--------------|---------|-------------|
| **N**                  | 828          | 172          |         |             |
| **Age, years**         | 35.5 [27.3, 48.5] | 34.2 [26.8, 42.1] | 0.409 | 0.0         |
| **Sex (% female)**     | 401 (48.4)   | 84 (48.8)    | 0.989   | 0.0         |
| **Race (%)**           |              |              | 0.861   | 2.0         |
| **Non-white**          | 45 (5.5)     | 10 (5.9)     |         |             |
| **Unknown/other**      | 90 (11.1)    | 21 (12.4)    |         |             |
| **White**              | 676 (83.4)   | 138 (81.7)   |         |             |
| **BMI, kg/m²**         | 26.0 [22.8, 30.0] | 26.2 [23.3, 29.6] | 0.461 | 0.8         |
| **Systolic blood pressure, mmHg** | 120.0 [111.0, 129.0] | 120.0 [110.5, 128.0] | 0.947 | 0.5         |
| **Diastolic blood pressure, mmHg** | 68.0 [60.0, 75.0] | 68.0 [59.5, 75.0] | 0.701 | 0.5         |
| **NYHA FC (%)**        |              |              | 0.614   | 0.0         |
| **I**                  | 624 (75.4)   | 135 (78.5)   |         |             |
| **II**                 | 177 (21.4)   | 31 (18.0)    |         |             |
| **III/IV**             | 27 (3.3)     | 6 (3.5)      |         |             |
| **Physiological stage (%)** |              |              | 0.312   | 0.0         |
| **A**                  | 43 (5.2)     | 14 (8.1)     |         |             |
| **B**                  | 193 (23.3)   | 40 (23.3)    |         |             |
| **C**                  | 483 (58.3)   | 91 (52.9)    |         |             |
| **D**                  | 109 (13.2)   | 27 (15.7)    |         |             |
| **Anatomic complexity (%)** |              |              | 0.399   | 0.0         |
| **Great complexity**   | 313 (37.8)   | 69 (40.1)    |         |             |
| **Moderate complexity**| 440 (53.1)   | 83 (48.3)    |         |             |
| **Simple**             | 75 (9.1)     | 20 (11.6)    |         |             |
| **Heart failure (%)**  | 35 (4.2)     | 5 (2.9)      | 0.555   | 0.0         |
| **CAD (%)**            | 7 (0.8)      | 0 (0.0)      | 0.479   | 0.0         |
| **Hypertension (%)**   | 118 (14.3)   | 21 (12.2)    | 0.560   | 0.0         |
| **Pulmonary hypertension (%)** | 34 (4.1)     | 9 (5.2)      | 0.648   | 0.0         |
| **Type 2 DM (%)**      | 35 (4.2)     | 5 (2.9)      | 0.555   | 0.0         |
| **Liver cirrhosis (%)**| 20 (2.4)     | 4 (2.3)      | 1.000   | 0.0         |
| **Chronic kidney disease (%)** | 9 (1.1)      | 3 (1.7)      | 0.737   | 0.0         |
| **Obstructive sleep apnea (%)** | 69 (8.3)     | 10 (5.8)     | 0.337   | 0.0         |
| **Cyanosis (O₂ saturation < 92%) (%)** | 64 (8.4)     | 18 (11.6)    | 0.257   | 8.1         |
| **Peak VO₂, % predicted** | 70.0 [59.0, 83.0] | 73.0 [62.0, 84.0] | 0.113 | 31.7        |
| **Systemic ventricular function (%)** |              |              | 0.227   | 0.2         |
| **Normal**             | 639 (77.3)   | 142 (83.0)   |         |             |
| **Borderline/mildly decreased** | 121 (14.6)   | 20 (11.7)    |         |             |
| **Moderately/severely decreased** | 67 (8.1)     | 9 (5.3)      |         |             |
| **Death or nonelective cardiovascular hospitalization (%)** | 165 (19.9)   | 20 (11.6)    | 0.015   | 0.0         |
| **Follow-up time, days** | 1043.0 [658.8, 1506.2] | 435.0 [293.8, 747.5] | <0.001 | 0.0         |
Categorical variables are presented as number (percent) and compared using Fisher’s exact test. Continuous variables are presented as mean (standard deviation) for normally distributed variables and as median [interquartile range] for non-normally distributed variables. Continuous variables are analyzed using the independent t-test (if normal distribution) or the Wilcoxon rank sums test (if non-normal distribution). Rate of death or non-elective cardiovascular hospitalization per year was compared with the Poisson test.

BMI = body mass index, NYHA FC = New York Heart Association Functional Class, CAD = coronary artery disease
Table S5. Hazard ratio and event rate for thromboembolic events, bleeding events, and catheter- or surgical-based intervention.

| # events | Thromboembolic event | Bleeding event | Catheter or surgical intervention |
|----------|----------------------|----------------|-----------------------------------|
|          | n/N (%) | HR | P value | n/N (%) | HR | P value | n/N (%) | HR | P value |
| IIA      | 0/17 (0.0) | -- | -- | 0/17 (0.0) | -- | -- | 0/17 (0.0) | -- | -- |
| IB       | 1/32 (3.1) | 1.94 | 0.541 | 0/32 (0.0) | -- | -- | 3/32 (9.4) | 0.37 | 0.093 |
| IC       | 0/31 (0.0) | -- | -- | 0/31 (0.0) | -- | -- | 3/31 (9.7) | 0.42 | 0.146 |
| ID       | 0/15 (0.0) | -- | -- | 0/15 (0.0) | -- | -- | 3/15 (20.0) | 0.80 | 0.699 |
| IIA      | 0/26 (0.0) | -- | -- | 0/26 (0.0) | -- | -- | 0/26 (0.0) | -- | -- |
| IIB      | 4/135 (3.0) | 1.54 | 0.506 | 1/135 (0.7) | 0.39 | 0.379 | 11/135 (8.1) | 0.30 | 0.000* |
| IIC      | 6/309 (1.9) | REFERENCE | REFERENCE | 6/309 (1.9) | REFERENCE | REFERENCE | 78/309 (25.2) | REFERENCE |
| IID      | 8/53 (15.1) | 7.89 | 0.000* | 6/53 (11.3) | 6.07 | 0.002* | 17/53 (32.1) | 1.09 | 0.761 |
| IIIA     | 0/14 (0.0) | -- | -- | 0/14 (0.0) | -- | -- | 0/14 (0.0) | -- | -- |
| IIIB     | 4/66 (6.1) | 2.74 | 0.119 | 0/66 (0.0) | -- | -- | 5/66 (7.6) | 0.25 | 0.003* |
| IIIC     | 11/234 (4.7) | 1.93 | 0.198 | 13/234 (5.6) | 2.09 | 0.147 | 49/234 (20.1) | 0.64 | 0.015* |
| IIID     | 7/68 (10.3) | 4.46 | 0.007* | 6/66 (8.8) | 4.33 | 0.011* | 27/68 (39.7) | 1.39 | 0.142 |

| C-statistic (95% CI) | 0.72 (0.68, 0.76) | 0.76 (0.72, 0.80) | 0.65 (0.63, 0.67) |

Values are presented by anatomic and physiological classification, with IIC as the reference group. Double dashes represent cells with no events. * indicates p-values <0.05.

HR = hazard ratio
Figure S1. Kaplan-Meier curve for survival free of the combined outcome of death or non-elective cardiovascular hospitalization for patients classified as either physiological stage A or B.

There were 290 patients classified as A or B. Curves are compared with the log-rank test.